Roche on Wednesday announced that it has received clearance from the Food and Drug Administration for its Accu-Chek Combo system for insulin pump therapy.
One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.
